Sexual Health & Libido — Peptide Research Overview
Sexual dysfunction encompasses reduced libido, erectile dysfunction, arousal disorders, and anorgasmia. Several melanocortin-pathway peptides have been studied specifically for centrally-mediated sexual desire — a mechanism distinct from phosphodiesterase inhibitors which address vascular function only.
Relevant Compounds
- PT-141 (Bremelanotide) — Vyleesi is an FDA-approved bremelanotide product for a specific premenopausal HSDD population; that approval does not apply to every product marketed as PT-141.
- Kisspeptin-10 — Hypothalamic neuropeptide that drives GnRH release and modulates sexual reward circuitry. Studied for psychosexual dysfunction.
- Melanotan II — Non-selective melanocortin agonist. Precursor to PT-141. Potent sexual arousal effects documented in human trials; not FDA-approved due to side effect profile.
What the Research Shows
PT-141 (Bremelanotide)
Vyleesi is an FDA-approved bremelanotide product for a specific premenopausal HSDD population. That approval cannot be generalized to every product sold as PT-141, other populations, or other outcomes. See the claim-level PT-141 evidence guide for the pivotal trials, limitations, and product distinctions.
Kisspeptin-10
[Human Trial — Preliminary] Kisspeptin drives GnRH pulsatility, which in turn stimulates LH and FSH. Human studies at Imperial College London show IV kisspeptin-54 enhances sexual brain processing (limbic/hypothalamic activation on fMRI) and reduces psychosexual dysfunction in patients with sexual aversion. Intranasal formulations are under investigation.
Melanotan II
[Human Trial — Phase 1/2] Early clinical trials at the University of Arizona demonstrated potent sexual arousal in men with erectile dysfunction, with erections occurring spontaneously at doses of 0.025 mg/kg. Not pursued to approval due to nausea, blood pressure changes, and tanning as side effects at effective doses. PT-141 was developed as a more selective, better-tolerated derivative.
Evidence Summary
| Compound | Evidence Level | FDA Status |
|---|---|---|
| Bremelanotide | Human Trial (Phase 3) | Specific product and indication approved (Vyleesi); not a blanket approval for PT-141 products |
| Kisspeptin-10 | Human Trial (Preliminary) | Not approved |
| Melanotan II | Human Trial (Phase 1/2) | Not approved |
Research Disclaimer
Vyleesi is an FDA-approved bremelanotide product for a specific HSDD population; this is not a blanket approval for products marketed as PT-141. No other compound listed on this page is FDA-approved for sexual health or libido. This page is an educational summary of existing research, not medical advice.
Track your compounds with Dosi
Log doses, monitor symptoms, and build a personal health timeline. Free to start.
Start Tracking Free →Educational use only. This content is for informational purposes only and does not constitute medical advice. Individual results vary. Always consult a licensed healthcare provider before starting any compound.